Endo, Inc. (OTCQX: NDOI) has recently solidified its presence in the Canadian pharmaceutical market through a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) via its subsidiary, Paladin Pharma Inc. This collaboration aims to provide a new treatment option for Canadians suffering from plaque psoriasis, a chronic skin condition that affects many individuals.
Livio Di Francesco, Vice President and General Manager of Paladin, expressed enthusiasm about the partnership, emphasizing the commitment to making Wynzora® Cream accessible to those affected by plaque psoriasis in Canada. He noted that if approved by Health Canada, Wynzora® Cream’s unique formulation is designed for ease of use, potentially enhancing patient adherence to treatment regimens.
Jesper J. Lange, CEO of MC2 Therapeutics, echoed this sentiment, highlighting the alignment of their objectives with Paladin’s expertise in the Canadian market. He stated that their goal is to ensure that Wynzora® Cream reaches as many patients as possible globally, thereby addressing an unmet need in psoriasis treatment.
Wynzora® Cream is a topical medication that combines calcipotriene and betamethasone dipropionate. This fixed-dose formulation works through a dual mechanism targeting key cytokines associated with inflammation in psoriasis. Specifically, it addresses the IL-23 and IL-17A/F immune pathways while also inhibiting TNF-α expression. The cream utilizes MC2’s innovative PAD Technology™, which enhances drug delivery and skin penetration, making it a convenient option for patients.
The cream has already seen success in other markets; it was approved by the FDA in the United States on July 20, 2020, and subsequently launched in Europe on February 18, 2022. These approvals underscore the product’s efficacy and safety profile, which have been demonstrated through rigorous clinical trials.
The Canadian dermatological market presents significant opportunities given the prevalence of plaque psoriasis among adults. According to recent estimates, millions of Canadians are affected by this condition, which often leads to physical discomfort and psychological distress. By introducing Wynzora® Cream into this market, Endo and Paladin Pharma aim to provide an effective treatment option that can improve patients’ quality of life.
Paladin Pharma has established itself as a key player in the Canadian pharmaceutical landscape by focusing on acquiring and licensing innovative products tailored for local needs. With a robust marketing and sales team, Paladin is well-positioned to effectively promote Wynzora® Cream once it receives regulatory approval.
Endo is a diversified specialty pharmaceutical company that focuses on transforming insights into life-enhancing therapies. Their commitment goes beyond product development, as they aim to provide essential medicines that improve patient outcomes.
Paladin Pharma Inc., based in Montreal, specializes in bringing innovative pharmaceutical products to Canada. As part of Endo’s operations, Paladin leverages its extensive experience and dedicated workforce to navigate the complexities of the Canadian healthcare system effectively.
The collaboration between Endo and MC2 Therapeutics is an opportunity to enhance patient care for those suffering from plaque psoriasis in Canada.
